JO3353B1 - شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي - Google Patents
شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقيInfo
- Publication number
- JO3353B1 JO3353B1 JOP/2013/0101A JOP20130101A JO3353B1 JO 3353 B1 JO3353 B1 JO 3353B1 JO P20130101 A JOP20130101 A JO P20130101A JO 3353 B1 JO3353 B1 JO 3353B1
- Authority
- JO
- Jordan
- Prior art keywords
- low
- anamolerin
- chloride
- organic solvent
- molar ratio
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Child & Adolescent Psychology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
يرتبط الاختراع الحالي بأشكال جسيمية من أحادي هيدروكلوريد الأناموريلين أو المركب الذي يحتوي على أحادي هيدروكلوريد الأناموريلين ذات محتوى الكلوريد المضبوط، الذي يفضل عزله في حالة عدم تبلور و/أو حالة جسيمية دقيقية، كما ويرتبط بعمليات صنع أشكال جسيمية ومركبات صيدلانية تحتوي على أشكال جسيمية.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261636108P | 2012-04-20 | 2012-04-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3353B1 true JO3353B1 (ar) | 2019-03-13 |
Family
ID=48225135
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2013/0101A JO3353B1 (ar) | 2012-04-20 | 2013-04-15 | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
Country Status (48)
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3353B1 (ar) | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| MY187167A (en) | 2014-09-04 | 2021-09-07 | Helsinn Healthcare Sa | Medical treatments based on anamorelin |
| CA3132620C (en) | 2015-07-24 | 2024-03-05 | Lumos Pharma, Inc. | Salts and prodrugs of 1-methyl-d-tryptophan |
| CN108239141A (zh) * | 2016-12-23 | 2018-07-03 | 江苏先声药业有限公司 | 一种阿拉莫林的制备方法 |
| CN115569119A (zh) * | 2019-08-30 | 2023-01-06 | 赫尔森保健股份公司 | 具有改善稳定性的阿拉莫林片剂的生产方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA73530C2 (uk) | 1999-11-10 | 2005-08-15 | Ново Нордіск А/С | Сполука з властивостями вивільнювати гормон росту |
| CN1882526A (zh) * | 2003-09-26 | 2006-12-20 | 兰贝克赛实验室有限公司 | 制备伏格列波糖的方法 |
| US7825138B2 (en) | 2004-06-29 | 2010-11-02 | Helsinn Therapeutics (U.S.), Inc. | Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
| KR20090112720A (ko) * | 2007-02-13 | 2009-10-28 | 헬신 세라퓨틱스 (유.에스.) 인크. | 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법 |
| UA105657C2 (uk) * | 2009-02-27 | 2014-06-10 | Хелсінн Терапьютікс (Ю.Ес.), Інк. | Поліпшені способи лікування мігрені на основі анамореліну |
| JO3353B1 (ar) * | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
-
2013
- 2013-04-15 JO JOP/2013/0101A patent/JO3353B1/ar active
- 2013-04-17 AR ARP130101264A patent/AR090725A1/es not_active Application Discontinuation
- 2013-04-18 JP JP2015507175A patent/JP6109925B2/ja active Active
- 2013-04-18 BR BR112014025972A patent/BR112014025972A8/pt not_active Application Discontinuation
- 2013-04-18 CA CA3031652A patent/CA3031652C/en active Active
- 2013-04-18 ES ES17192651T patent/ES2820354T3/es active Active
- 2013-04-18 EP EP13719344.7A patent/EP2838892B1/en active Active
- 2013-04-18 PL PL13719344T patent/PL2838892T3/pl unknown
- 2013-04-18 MY MYPI2014703092A patent/MY170068A/en unknown
- 2013-04-18 PT PT137193447T patent/PT2838892T/pt unknown
- 2013-04-18 ME MEP-2018-47A patent/ME02966B/me unknown
- 2013-04-18 TW TW106105466A patent/TWI677494B/zh active
- 2013-04-18 US US13/865,649 patent/US20140018391A1/en not_active Abandoned
- 2013-04-18 HR HRP20180316TT patent/HRP20180316T1/hr unknown
- 2013-04-18 GE GEAP201813634A patent/GEAP201813634A/en unknown
- 2013-04-18 MD MDA20140122A patent/MD4615C1/ro active IP Right Grant
- 2013-04-18 ES ES13719344.7T patent/ES2658862T3/es active Active
- 2013-04-18 LT LTEP13719344.7T patent/LT2838892T/lt unknown
- 2013-04-18 KR KR1020197011485A patent/KR102141323B1/ko active Active
- 2013-04-18 UA UAA201412382A patent/UA116207C2/uk unknown
- 2013-04-18 EP EP19155007.8A patent/EP3517532B1/en active Active
- 2013-04-18 NZ NZ700833A patent/NZ700833A/en unknown
- 2013-04-18 MX MX2014012178A patent/MX354793B/es active IP Right Grant
- 2013-04-18 PE PE2014001624A patent/PE20150084A1/es not_active Application Discontinuation
- 2013-04-18 SI SI201331789T patent/SI3290410T1/sl unknown
- 2013-04-18 SI SI201330963T patent/SI2838892T1/en unknown
- 2013-04-18 TW TW102113767A patent/TWI589572B/zh active
- 2013-04-18 SG SG11201406478XA patent/SG11201406478XA/en unknown
- 2013-04-18 WO PCT/US2013/037159 patent/WO2013158874A1/en not_active Ceased
- 2013-04-18 AP AP2014008013A patent/AP2014008013A0/xx unknown
- 2013-04-18 PL PL17192651T patent/PL3290410T3/pl unknown
- 2013-04-18 EA EA201401151A patent/EA031581B1/ru unknown
- 2013-04-18 MA MA37524A patent/MA37524B1/fr unknown
- 2013-04-18 HU HUE17192651A patent/HUE050865T2/hu unknown
- 2013-04-18 CN CN201380003026.5A patent/CN103857669B/zh active Active
- 2013-04-18 CN CN201910323598.0A patent/CN110041304A/zh active Pending
- 2013-04-18 DK DK13719344.7T patent/DK2838892T3/en active
- 2013-04-18 GE GEAP201313634A patent/GEP20186902B/en unknown
- 2013-04-18 PT PT191550078T patent/PT3517532T/pt unknown
- 2013-04-18 CA CA2869893A patent/CA2869893C/en active Active
- 2013-04-18 KR KR1020147018116A patent/KR101972998B1/ko active Active
- 2013-04-18 EP EP17192651.2A patent/EP3290410B1/en active Active
- 2013-04-18 HU HUE13719344A patent/HUE035697T2/en unknown
- 2013-04-18 SG SG10201608488RA patent/SG10201608488RA/en unknown
- 2013-04-18 RS RS20180192A patent/RS56869B1/sr unknown
- 2013-04-18 CN CN201910323606.1A patent/CN110041398A/zh active Pending
- 2013-04-18 AU AU2013249197A patent/AU2013249197B2/en active Active
- 2013-04-18 DK DK19155007.8T patent/DK3517532T3/da active
- 2013-04-19 PY PY201301316881A patent/PY1316881A/es unknown
- 2013-04-19 UY UY0001034753A patent/UY34753A/es active IP Right Grant
- 2013-07-29 NO NO13823572A patent/NO2877697T3/no unknown
-
2014
- 2014-10-07 IL IL235064A patent/IL235064B/en active IP Right Grant
- 2014-10-08 TN TN2014000421A patent/TN2014000421A1/fr unknown
- 2014-10-20 DO DO2014000235A patent/DOP2014000235A/es unknown
- 2014-10-20 CL CL2014002817A patent/CL2014002817A1/es unknown
- 2014-10-20 NI NI201400124A patent/NI201400124A/es unknown
- 2014-10-20 PH PH12014502351A patent/PH12014502351B1/en unknown
- 2014-11-12 US US14/539,318 patent/US9403867B2/en active Active
- 2014-11-18 EC ECIEPI201427739A patent/ECSP14027739A/es unknown
- 2014-11-19 ZA ZA2014/08508A patent/ZA201408508B/en unknown
- 2014-11-19 CR CR20140530A patent/CR20140530A/es unknown
- 2014-11-20 CO CO14255094A patent/CO7131356A2/es unknown
-
2016
- 2016-04-21 US US15/135,147 patent/US9872883B2/en active Active
- 2016-04-21 US US15/135,051 patent/US9981002B2/en active Active
- 2016-04-21 US US15/135,107 patent/US9956261B2/en active Active
-
2017
- 2017-03-08 JP JP2017043785A patent/JP6284665B2/ja active Active
-
2018
- 2018-01-30 JP JP2018013782A patent/JP6616853B2/ja active Active
- 2018-03-05 CY CY20181100270T patent/CY1120276T1/el unknown
- 2018-04-26 US US15/963,284 patent/US10300105B2/en active Active
- 2018-06-28 HK HK18108293.7A patent/HK1248694A1/en unknown
-
2019
- 2019-04-14 US US16/383,623 patent/US10576122B2/en active Active
-
2020
- 2020-01-24 US US16/751,836 patent/US10905737B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20180102B1 (ar) | مركب صيدلاني | |
| EA201300388A1 (ru) | Соединения замещенного бензамида | |
| EA201400833A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| EA201591527A1 (ru) | Новые производные пиридина | |
| UA108101C2 (xx) | Похідні n3-заміщених n1-сульфоніл-5-фторпіримідинонів | |
| EA201591064A1 (ru) | Новые производные пиридина | |
| SI3066085T1 (sl) | Postopek sinteze inhibitorja indolamina 2,3-dioksigenaze | |
| MX2015012628A (es) | Compuestos de tetrahidropirrolotiazina. | |
| UA110470C2 (ru) | Антидот антикоагулянта | |
| EA201600124A1 (ru) | Новые индолизиновые соединения, способ их получения и фармацевтические композиции, содержащие их | |
| MX2015010106A (es) | Moduladores de la proteina activadora de 5-lipoxigenasa. | |
| EA201691216A1 (ru) | Композиции линаклотида с замедленным высвобождением | |
| EA201591624A1 (ru) | Новые производные пиразола | |
| EA201300034A1 (ru) | Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения | |
| EP3050884A4 (en) | Novel chemical compounds (variants) and the use thereof to treat oncological diseases | |
| IL241245A (en) | Bicyclo [2.2.1] acid gpr120 modulators | |
| JO3353B1 (ar) | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي | |
| HK1221645A1 (zh) | Vmat2的苯并喹啉抑制剂 | |
| MX2016004393A (es) | Derivados de carboxamida como compuestos pesticidas. | |
| HK1213880A1 (zh) | 环胺 | |
| PH12014501840A1 (en) | Pharmaceutical formulation having improved stability | |
| MX2015007309A (es) | Derivado de hidantoina. | |
| GB201020397D0 (en) | Compounds | |
| WO2014172363A3 (en) | Combretastatin analogs | |
| IN2014DN07191A (ar) |